Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 ...

Find insight on GSK, Novo Nordisk, tariff escalation and more in the latest Market Talks covering Health Care.

GSK was able to offset the decline thanks to a better-than-expected performance for its cancer medicines and HIV therapeutics ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

A jab given to patients to battle RSV through the NHS could potentially cause a disabling condition known as Guillain-Barré ...

GSK Plc (NYSE:GSK) reported fourth-quarter sales of $10.40 billion (8.12 billion Sterling Pounds), up 1% year-over-year and ...

GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...

The FDA will review a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted).

GSK (LON:GSK) has raised its long-term revenue outlook, now expecting sales to exceed 40 billion by 2031, up from 38 billion.

GSK has today posted a better-than-expected fourth quarter and lifted its 2031 sales target to nearly $50 billion as the ...

Pharmaceuticals giant GlaxoSmithKline ( GSK.L) (GSK) has lifted its long-term sales guidance as it hailed a strong drugs ...